Amorese to integrate R&D resources, expand product portfolio, and tap new markets
SAN CARLOS, Calif.–NuGEN Technologies, Inc., a privately held company that develops and commercializes nucleic acid amplification and labeling systems announced today that it has hired Dr. Douglas A. Amorese to serve as the company’s vice president of research and development, a new position reporting to Elizabeth Hutt, chief executive officer.
Dr. Amorese will oversee all research and development. He will actively work with founder and chief scientific officer, Dr. Nurith Kurn, to further mine NuGEN’s extensive intellectual property portfolio and diversify the company’s product pipeline. Dr. Amorese will also work with vice president of development, Dr. Garry Miyada, to accelerate the introduction of product families and applications that address the needs of life science researchers and provide entry into new market sectors.
“Doug’s extensive background in genomics, microarray technologies, and product commercialization will allow NuGEN to capitalize on the breakthroughs we’ve made in amplification and labeling,” noted Dr. Kurn. “Our proprietary technologies have proven powerful and versatile, and we’re anxious to make them available to scientists investigating causes and pathologies of diseases such as cancer, metabolic disorders, and more.”
Most recently director of research and development for Agilent’s genomics group, Amorese was responsible for all new product development projects related to the company’s DNA microarray business, including array content and design, fabrication and processing technologies, automation, image acquisition (scanning), data analysis and QC. Prior to Agilent, he held positions of increasing responsibility with DuPont and Life Technologies.
Dr. Miyada explained, “The development team is looking forward to working with Doug to create successful strategies for new products and applications. Our customers are tremendously enthusiastic about NuGEN Ovation® Systems, and frequently challenge us to develop products and solutions to address their specific needs. Integrating research and development will enable us to respond quickly and efficiently.”
Amorese earned a PhD in biochemistry at Colorado State University, and served post-doctoral fellowships at the Salk Institute and at the University of Texas Health Science Center.
NuGEN Technologies, Inc. (www.nugeninc.com), based in San Carlos, CA, is focused on the development and commercialization of sensitive, rapid, and high-throughput nucleic acid amplification and labeling systems to enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies.
NuGEN, Ovation, SPIA, and Ribo-SPIA, are registered trademarks of NuGEN Technologies, Inc. WT-Ovation, FL-Ovation, and Imagine More From Less are trademarks or service marks of NuGEN Technologies, Inc. All other marks are the property of their respective owners.